GSK Proposes Adding OTC Oral Spray To US Smoking Cessation Sector
Executive Summary
FDA schedules Nonprescription Drugs Advisory Committee meeting 18 September to consider GSK's NDA for an OTC nicotine oral spray that delivers 1mg per spray.
You may also be interested in...
Sweden’s Enorama Looking To Break Into US And Europe’s Crowded NRT Markets
HBW Insight speaks to Swedish R&D firm Enorama's vice president Annette Agerskov about the company's plans to enter US and European OTC nicotine replacement therapy markets with a new, consumer-friendly nicotine gum.
US Health Market In 2019: Unfinished Business Leaves Lasting Impression
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
NRT Delivery Innovation Proposal In US Doesn't Deliver Expanded Indications
GSK's proposed usage for mouth spray product – reducing withdrawal symptoms, including nicotine craving – differs little from the first NRT product approved in US in 1984. Additional suggested label instructions primarily focus on stating NRTs can be used to reduce smoking or gradually stop tobacco use as opposed to quitting within a specified amount of time.